9 reports

Drivers and Their Impact Impact on Key Customer Category Driver Rise in Accidents and Violence Increased R& D Patient Assistance Programs Low Low ## ## ## ## ## High High ## ## ## ## ## Hospitals Low High ## ## ## ## ## Low Pharmaceutical Stores High ## ## ## ## ## Low Low

  • Anxiety Disorder
  • Azevan Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.

Drivers and their Impact Impact on Key Customer Category Patient Increased Population Co-morbidity Anxiety Illnesses and between Other Designated ICD-## Code Low ## ## ## ## ## High Low High ## ## ## ## ## Low ## ## ## ## ## Low High ## ## ## ## ## Low ## ## ## ## ## High Increas

  • Anxiety Disorder
  • World
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Pfizer Inc.

Patients will be randomized to receive one of two doses of BNC## (##mg or 2000mg) or one of two controls, placebo or ##. ##mg Lorazepam.

  • Anxiety Disorder
  • United States
  • World
  • Product Initiative
  • Bionomics

Patients will be randomized to receive one of two doses of BNC## (##mg or 2000mg) or one of two controls, placebo or ##. ##mg Lorazepam.

  • Anxiety Disorder
  • Therapy
  • United States
  • Product Initiative
  • Bionomics

NO has a solid place in asthma management.

  • Drug Test
  • United States
  • Alere Inc.
  • Dräger Group
  • Thermo Fisher Scientific, Inc.

The prominent features of this report are - ##.

  • Anxiety Disorder
  • Chronic Pain
  • Clinical Trial
  • Pharmaceutical
  • Eli Lilly & Co.

THE EXISTING PRODUCT PORTFOLIO AND THE PIPELINE CANDIDATES ARE TARGETED FOR TREATING PATIENTS OF EPILEPSY, ANXIETY, DEPRESSION, ASTHMA, PAIN, ALLERGIC RHINITIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASES.

  • Anxiety Disorder
  • United States
  • Company
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • PEPTIDE TO ACTIVATE NPSR FOR SLEEP DISORDERS AND ANXIETY DISORDERS - DRUG PROFILE

In this trial, over ## patients will be randomized to receive one of four treatments ## mg ITI-##, ## mg ITI-##, ## mg risperidone (active control) or placebo in a ##:##:##:## ratio.

  • Anxiety Disorder
  • Pharmaceutical
  • United States
  • Company
  • Product Initiative

IN THIS TRIAL, OVER ## PATIENTS WILL BE RANDOMIZED TO RECEIVE ONE OF FOUR TREATMENTS ## MG ITI-##, ## MG ITI-##, ## MG RISPERIDONE (ACTIVE CONTROL) OR PLACEBO IN A ##:##:##:## RATIO.

  • Anxiety Disorder
  • Pharmaceutical
  • Research And Development
  • United States
  • Company Operations